(Q30426728)

6 November 2017

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab (English)

1 reference

6 November 2017

1 reference

1 reference

16

Henry S Friedman

1 reference

6 November 2017

6

Patrick Y Wen

1 reference

6 November 2017

2

Timothy Cloughesy

1 reference

6 November 2017

5

Michael Prados

1 reference

6 November 2017

11

Nina Paleologos

1 reference

6 November 2017

9

Lauren E Abrey

1 reference

6 November 2017

Jeffrey S Wefel

1

1 reference

6 November 2017

James L Zazzali

3

1 reference

6 November 2017

Maoxia Zheng

4

1 reference

6 November 2017

Tom Mikkelsen

7

1 reference

6 November 2017

David Schiff

8

1 reference

6 November 2017

W K Alfred Yung

10

1 reference

6 November 2017

Martin K Nicholas

12

1 reference

6 November 2017

Randy Jensen

13

1 reference

6 November 2017

James Vredenburgh

14

1 reference

6 November 2017

Asha Das

15

1 reference

6 November 2017

language of work or name

1 reference

9 May 2011

1 reference

6 November 2017

1 reference

6 November 2017

13

1 reference

6 November 2017

6

1 reference

6 November 2017

660-668

1 reference

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

6 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Longitudinal changes in memory and executive functioning are associated with longitudinal change in instrumental activities of daily living in older adults

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

The course of neurocognitive functioning in high-grade glioma patients.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Facets and determinants of quality of life in patients with recurrent high grade glioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Normative data for determining significance of test-retest differences on eight common neuropsychological instruments.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Neurotoxicity of CI-980, a novel mitotic inhibitor

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma

20 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Benton Controlled Oral Word Association Test: reliability and updated norms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Practice effects during repeated administrations of memory tests with and without alternate forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Cognitive deficits before treatment among patients with brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

The prognostic value of cognitive functioning in the survival of patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR024

Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Response criteria for phase II studies of supratentorial malignant glioma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107095

Clinical significance: A statistical approach to defining meaningful change in psychotherapy research

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21558074

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOR024

1 reference

6 November 2017

1 reference

6 November 2017

PubMed publication ID

21558074

1 reference